PCVX
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Vaxcyte, Inc. - Common Stock (PCVX) [ST]
www.vaxcyte.com ↗▲ 0.67%
prev close
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Congressional Trades
3
All tracked trades
Members Trading
3
Unique members
Net Activity
+1
2 buys · 1 sells
Members Who Traded This Stock
3 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-04-15 | PCVXVaxcyte, Inc. - Common Stock | Buy | $1,001 - $15,000 | 331d ago | — | |
| 2025-03-05 | PCVXVaxcyte, Inc. - Common Stock | Sell | $15,001 - $50,000 | 356d ago | — | |
| 2022-11-08 | PCVXVaxcyte, Inc. - Common Stock | Buy | $1,001 - $15,000 | 1207d ago | — |
2025-04-15
Gilbert Cisneros
PCVX
Amount
$1,001 - $15,000
Filed
331d ago
2025-03-05
Jefferson Shreve
PCVX
Amount
$15,001 - $50,000
Filed
356d ago
2022-11-08
Christopher L. Jacobs
PCVX
Amount
$1,001 - $15,000
Filed
1207d ago
Recent News
Powered by Polygon.io
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Vaxcyte Announces Pricing of $550 Million Public Offering
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown
Trade Timeline
Congressional activity, newest first
Gilbert Cisneros
2025-04-15 · Purchase
$1,001 - $15,000
Jefferson Shreve
2025-03-05 · Sale
$15,001 - $50,000
Christopher L. Jacobs
2022-11-08 · Purchase
$1,001 - $15,000